Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2
Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.
Stocks · News reference
BTIG Downgrades Foghorn Therapeutics to Neutral
BTIG analyst Jeet Mukherjee downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Buy to Neutral.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Foghorn Therapeutics shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.
TD Cowen Downgrades Foghorn Therapeutics to Hold
TD Cowen analyst Yaron Werber downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Buy to Hold.
Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5